Combinatorial nanomedicines for colon cancer therapy (Q38523659)

3 September 2017

1 reference

title

Combinatorial nanomedicines for colon cancer therapy (English)

1 reference

3 September 2017

1 reference

1 reference

A Anitha

1

1 reference

3 September 2017

S Maya

2

1 reference

3 September 2017

Amal J Sivaram

3

1 reference

3 September 2017

U Mony

4

1 reference

3 September 2017

R Jayakumar

5

1 reference

3 September 2017

10 June 2015

1 reference

Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology

3 September 2017

1 reference

3 September 2017

8

1 reference

3 September 2017

1

1 reference

3 September 2017

151-159

1 reference

Differences in survival between colon and rectal cancer from SEER data

3 September 2017

1 reference

Estimates of the worldwide mortality from eighteen major cancers in 1985. Implications for prevention and projections of future burden

21 January 2018

1 reference

Mass screening for colorectal cancer.

21 January 2018

1 reference

Differential effects of arsenic trioxide on chemosensitization in human hepatic tumor and stellate cell lines

21 January 2018

1 reference

Schedule-dependent antitumor effects of 5-fluorouracil combined with sorafenib in hepatocellular carcinoma

21 January 2018

1 reference

Single-agent therapy with sorafenib or 5-FU is equally effective in human colorectal cancer xenograft--no benefit of combination therapy

21 January 2018

1 reference

Antitumor effect of 5-fluorouracil is enhanced by rosemary extract in both drug sensitive and resistant colon cancer cells.

21 January 2018

1 reference

Combined 5-FU and ChoKα inhibitors as a new alternative therapy of colorectal cancer: evidence in human tumor-derived cell lines and mouse xenografts.

21 January 2018

1 reference

Curcumin enhances the effect of chemotherapy against colorectal cancer cells by inhibition of NF-κB and Src protein kinase signaling pathways

21 January 2018

1 reference

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

21 January 2018

1 reference

Polysaccharides-based nanoparticles as drug delivery systems

21 January 2018

1 reference

Biodegradable nanoparticles for oral delivery of peptides: is there a role for polymers to affect mucosal uptake?

21 January 2018

1 reference

Nanoencapsulation I. Methods for preparation of drug-loaded polymeric nanoparticles.

21 January 2018

1 reference

Targeted polymeric therapeutic nanoparticles: design, development and clinical translation

21 January 2018

1 reference

Optimization of size and encapsulation efficiency of 5-FU loaded chitosan nanoparticles by response surface methodology

21 January 2018

1 reference

Nanoparticles in medicine: therapeutic applications and developments

21 January 2018

1 reference

Half-antibody functionalized lipid-polymer hybrid nanoparticles for targeted drug delivery to carcinoembryonic antigen presenting pancreatic cancer cells.

21 January 2018

1 reference

Therapeutic nanoparticles to combat cancer drug resistance

21 January 2018

1 reference

Nanoparticle-based combination therapy toward overcoming drug resistance in cancer

21 January 2018

1 reference

Active targeting schemes for nanoparticle systems in cancer therapeutics

21 January 2018

1 reference

Nanoparticulate systems for nasal delivery of drugs: a real improvement over simple systems?

21 January 2018

1 reference

pH-sensitive poly(histidine)-PEG/DSPE-PEG co-polymer micelles for cytosolic drug delivery

21 January 2018

1 reference

Nanoparticle and targeted systems for cancer therapy

21 January 2018

1 reference

Liposomes and nanoparticles: nanosized vehicles for drug delivery in cancer

21 January 2018

1 reference

Polymeric drugs for efficient tumor-targeted drug delivery based on EPR-effect

21 January 2018

1 reference

Nanoparticle delivery of cancer drugs.

21 January 2018

1 reference

NK105, a paclitaxel-incorporating micellar nanoparticle formulation, can extend in vivo antitumour activity and reduce the neurotoxicity of paclitaxel

21 January 2018

1 reference

The EPR effect: Unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effect

21 January 2018

1 reference

The enhanced permeability and retention (EPR) effect in tumor vasculature: the key role of tumor-selective macromolecular drug targeting

21 January 2018

1 reference

Angiogenesis in cancer and other diseases

21 January 2018

1 reference

Therapeutic nanoparticles for drug delivery in cancer

21 January 2018

1 reference

Nanoparticle therapeutics: an emerging treatment modality for cancer

21 January 2018

1 reference

Nanocarriers as an emerging platform for cancer therapy

21 January 2018

1 reference

Combination drug delivery approaches in metastatic breast cancer

21 January 2018

1 reference

Encapsulation of curcumin in alginate-chitosan-pluronic composite nanoparticles for delivery to cancer cells.

21 January 2018

1 reference

Synthesis of novel biodegradable and self-assembling methoxy poly(ethylene glycol)-palmitate nanocarrier for curcumin delivery to cancer cells

21 January 2018

1 reference

Polymeric nanoparticle-encapsulated curcumin ("nanocurcumin"): a novel strategy for human cancer therapy

21 January 2018

1 reference

Biocompatible, biodegradable and thermo-sensitive chitosan-g-poly (N-isopropylacrylamide) nanocarrier for curcumin drug delivery.

21 January 2018

1 reference

Nanoencapsulation of polyphenols for protective effect against colon-rectal cancer.

21 January 2018

1 reference

Delivery of antiinflammatory nutraceuticals by nanoparticles for the prevention and treatment of cancer

21 January 2018

1 reference

Nanoparticle therapeutics for prostate cancer treatment

21 January 2018

1 reference

Expert opinion: Responsive polymer nanoparticles in cancer therapy

21 January 2018

1 reference

Polymers and nanoparticles: intelligent tools for intracellular targeting?

21 January 2018

1 reference

Nanoparticles: Emerging carriers for drug delivery

21 January 2018

1 reference

Cetuximab-conjugated magneto-fluorescent silica nanoparticles for in vivo colon cancer targeting and imaging

21 January 2018

1 reference

Cetuximab conjugated O-carboxymethyl chitosan nanoparticles for targeting EGFR overexpressing cancer cells

21 January 2018

1 reference

Folic acid conjugated guar gum nanoparticles for targeting methotrexate to colon cancer.

21 January 2018

1 reference

Targeted human serum albumin nanoparticles for specific uptake in EGFR-Expressing colon carcinoma cells.

21 January 2018

1 reference

Folic acid-PEG conjugated superparamagnetic nanoparticles for targeted cellular uptake and detection by MRI.

21 January 2018

1 reference

Folic acid-conjugated chitosan nanoparticles enhanced protoporphyrin IX accumulation in colorectal cancer cells

21 January 2018

1 reference

Therapeutic modalities of squalenoyl nanocomposites in colon cancer: an ongoing search for improved efficacy

21 January 2018

1 reference

Insulin decreases therapeutic efficacy in colon cancer cell line HT29 via the activation of the PI3K/Akt pathway

21 January 2018

1 reference

In vitro combinatorial anticancer effects of 5-fluorouracil and curcumin loaded N,O-carboxymethyl chitosan nanoparticles toward colon cancer and in vivo pharmacokinetic studies

21 January 2018

1 reference

Combinatorial anticancer effects of curcumin and 5-fluorouracil loaded thiolated chitosan nanoparticles towards colon cancer treatment.

21 January 2018

1 reference

Cytotoxicity of anticancer drugs incorporated in solid lipid nanoparticles on HT-29 colorectal cancer cell line.

21 January 2018

1 reference

Macromolecular drug carrier systems in cancer chemotherapy: macromolecular prodrugs

21 January 2018

1 reference

Drug-polymer conjugates containing acid-cleavable bonds

21 January 2018

1 reference

Self-assembled cationic peptide nanoparticles as an efficient antimicrobial agent

21 January 2018

1 reference

Nanoparticle technologies for cancer therapy

21 January 2018

1 reference

Polymer-drug conjugates: current status and future trends

21 January 2018

1 reference

Primary colon cancer: ESMO Clinical Practice Guidelines for diagnosis, adjuvant treatment and follow-up

21 January 2018

1 reference

Actively targeted cetuximab conjugated gamma-poly(glutamic acid)-docetaxel nanomedicines for epidermal growth factor receptor over expressing colon cancer cells.

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1002/WNAN.1353

1 reference

3 September 2017

1 reference